Your new post is loading...
The Food and Drug Administration on Friday approved Mitsubishi Tanabe Pharma Corp's treatment for fatal neurological disorder amyotrophic lateral sclerosis (ALS), marking the first such U.S. regulatory approval in more than two decades.
Scoop.it!
No comment yet.
Sign up to comment
